EGFR Antibody (ICR10) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB600-724
![Flow Cytometry: EGFR Antibody (ICR10) - BSA Free [NB600-724]](https://resources.bio-techne.com/images/products/EGF-R-ErbB1-Antibody-ICR10-Flow-Cytometry-NB600-724-img0003.jpg "Flow Cytometry: EGFR Antibody (ICR10) - BSA Free [NB600-724]")
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Flow Cytometry, Immunofluorescence, Immunoprecipitation, Western Blot (Negative)
Cited:
Flow Cytometry, In vivo assay
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG2A Clone # ICR10
Format
BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Extracellular domain of human EGF-receptor from head and neck carcinoma
Epitope
ICR10 binds to epitope B, and has an affinity of 6.7x10-9 M.
Localization
Cell Membrane and Secreted
Specificity
EGFR. It does not react with erb-B2.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2A
Scientific Data Images for EGFR Antibody (ICR10) - BSA Free
Flow Cytometry: EGFR Antibody (ICR10) - BSA Free [NB600-724]
Flow Cytometry: EGF R/ErbB1 Antibody (ICR10) [NB600-724] - Analysis using the FITC conjugate of NB600-724. Staining of A431 cells.![Flow Cytometry: EGFR Antibody (ICR10) - BSA Free [NB600-724]](https://resources.bio-techne.com/images/products/EGF-R-ErbB1-Antibody-ICR10-Flow-Cytometry-NB600-724-img0001.jpg "Flow Cytometry: EGFR Antibody (ICR10) - BSA Free [NB600-724]")
Flow Cytometry: EGFR Antibody (ICR10) - BSA Free [NB600-724]
Flow Cytometry: EGF R/ErbB1 Antibody (ICR10) [NB600-724] - Staining of A431 cells with RAT ANTI HUMAN EGF RECEPTOR (NB 600-724) visualised with F(ab')2 RABBIT ANTI RAT IgG: FITC secondary.Applications for EGFR Antibody (ICR10) - BSA Free
Application
Recommended Usage
Flow Cytometry
1:50-1:100
Immunohistochemistry
1:10-1:500
Immunohistochemistry-Frozen
1:10-1:500
Immunohistochemistry-Paraffin
1:10-1:500
Immunoprecipitation
1:10-1:500
Application Notes
For Flow Cytometry: Use 10 ul of the suggested working dilution to label 10^6 cells in 100 ul.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: EGFR
In addition to its role in normal development, EGFR mutations or overexpression is observed in many tumors, including breast cancer, non-small cell lung carcinoma (NSCLC), colon cancer, and more (3-6). Small molecule tyrosine kinase inhibitors (TKIs), like gefitinib, erlotinib, and afatinib, have shown great efficacy in treating patients with EGFR activating mutations, especially for NSCLC (4-6). However, most patients eventually develop acquired resistance to TKIs and thus combination and alternative therapies are in development (4-6). A third-generation TKI, osimertinib, is approved for NSCLC patients with resistance to first-line EGFR TKI treatment (6). Additionally, combination therapies of EGFR TKIs with monoclonal antibody immunotherapies, like anti-PD-L1, are being further investigated in clinical trials (6).
References
1. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019; 139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014
2. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12(1):3-20. https://doi.org/10.1002/1878-0261.12155
3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018
4. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. https://doi.org/10.1186/s12943-018-0793-1
5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020; 61:167-179. https://doi.org/10.1016/j.semcancer.2019.09.015
6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1
Long Name
Epidermal Growth Factor Receptor
Alternate Names
EGF R, ErbB, ErbB1, HER-1
Gene Symbol
EGFR
UniProt
Additional EGFR Products
Product Documents for EGFR Antibody (ICR10) - BSA Free
Product Specific Notices for EGFR Antibody (ICR10) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...